Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash & Current Investments: 2015-2025

Historic Cash & Current Investments for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to $208.9 million.

  • Voyager Therapeutics' Cash & Current Investments fell 39.50% to $208.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $927.2 million, marking a year-over-year decrease of 31.15%. This contributed to the annual value of $266.7 million for FY2024, which is 15.51% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Cash & Current Investments is $208.9 million, which was down 3.09% from $215.6 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Cash & Current Investments ranged from a high of $399.6 million in Q1 2024 and a low of $118.8 million during Q4 2022.
  • Moreover, its 3-year median value for Cash & Current Investments was $266.7 million (2024), whereas its average is $279.4 million.
  • In the last 5 years, Voyager Therapeutics' Cash & Current Investments surged by 94.26% in 2023 and then plummeted by 41.89% in 2025.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' Cash & Current Investments stood at $132.5 million in 2021, then decreased by 10.33% to $118.8 million in 2022, then surged by 94.26% to $230.9 million in 2023, then climbed by 15.51% to $266.7 million in 2024, then crashed by 39.50% to $208.9 million in 2025.
  • Its Cash & Current Investments stands at $208.9 million for Q3 2025, versus $215.6 million for Q2 2025 and $236.0 million for Q1 2025.